Table 19Association between progesterone receptor (PR) status and outcomes

Included TreatmentsAuthor, YearNumber of WomenEstimate/DesignMonths of FollowupPR StatusRelative Measure of the Association (95% CI)
Any Recurrence
M, LR, LT, or LKepple, 200638094OR/Observational study48Positive vs. negative0.138 (0.016, 1.236)
M, MR, LRT, LT, LR, or LDawood, 2008351399OR/Observational study34.8Positive vs. negative2.089 (0.445, 9.812)
Local DCIS or Invasive Carcinoma
LRT, LR, LT, or LProvenzano, 200338195OR/Observational study*101Positive vs. negative0.4 (0.2, 0.9)
L, LR, LT, or LRTRoka, 2004342122OR/Observational study61.6Positive vs. negative0.37 (0.072, 1.913)
LRingberg, 2001379121RR/Observational study62Positive vs. negative0.6 (0.3, 1.3)
M, LR or Lde Roos, 200733087HR/Observational study*49.8Positive vs. negative0.909 (0.333, 2.5)

Bold = Statistically significant

*

Multivariate adjusted

L=Lumpectomy; M=Mastectomy; R=Radiation; T=Tamoxifen

From: 3, Results

Cover of Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)
Diagnosis and Management of Ductal Carcinoma in Situ (DCIS).
Evidence Reports/Technology Assessments, No. 185.
Virnig BA, Shamliyan T, Tuttle TM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.